Pathogenesis of antiphospholipid antibodies : Impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway
スポンサーリンク
概要
- 論文の詳細を見る
Antiphospholipid syndrome (APS) is characterized by recurrent thrombosis or pregnancy morbidity associated with antiphospholipid antibodies (aPL). Impaired fibrinolysis is a contributing factor for the development of thrombosis, and the effect of aPL in the fibrinolytic system has been investigated. Impaired release of tPA and enhanced release of PAI-1 after endothel activation is reported in patients with APS. Elevated Lipoprotein (a) levels have been found in APS, which results in inhibition of fibrinolytic activity. Phospholipid-bound β2-glycoprotein I (β2GPI) is a major autoantigen for aPLs. β2GPI exerts both anti-coagulant and pro-coagulant properties mainly by interacting with other phospholipid-binding proteins such as coagulation factors and protein C. Dramatic increase in the affinity of β2GPI to the cell surface is induced by binding of pathogenic anti-β2GPI antibodies, which may modify the physiological function of β2GPI and may affect the coagulation/fibrinolysis balance on the cell surface. Using chromogenic assays for measuring fibrinolytic activity, we demonstrated that addition of monoclonal anticardiolipin antibody (aCL) decreases the activity of extrinsic/intrinsic fibrinolysis. Significantly lower activity of intrinsic fibrinolysis was also demonstrated in the euglobulin fractions from APS patients. Endothelial cells and monocytes are activated by aPLs in vitro, resulting in production of tissue factor (TF), a major initiator of the coagulation system. Recently, aPLs are reported to induce thrombocytes to produce thromboxane. The importance of apoE receptor 2 on platelets for the binding of artificially-dimerized β2GPI was suggested. By investigating aPL-inducible genes in peripheral blood mononuclear cells, we found that mitogen-activated protein kinase (MAPK) pathway was up-regulated. Using monocyte cell line, phosphorylation of p38 MAPK, NF-κB translocation to the nuclear fraction, and up-regulated TF mRNA expression were demonstrated after treatment with monoclonal aCL. These phenomena were observed only in the presence of β2GPI. Moreover, a specific p38 MAPK inihibitor SB203580 decreased aCL/β2GPI-induced TF mRNA expression. Thus, aCL/β2GPI plays dual roles in the pathogenesis of APS, firstly by deranging fibrinolytic system and secondly by activating monocytes, endothelial cells and thrombocytes to produce tissue factor or thromboxane.http://www.sciencedirect.com/science/journal/01712985
- Elsevierの論文
- 2005-12-13
著者
-
ATSUMI Tatsuya
Department of Medicine II, Hokkaido University Graduate School of Medicine
-
Koike Takao
Hokkaido Univ. Graduate School Of Medicine Sapporo Jpn
-
Atsumi Tatsuya
Hokkaido Univ. Graduate School Of Medicine Sapporo Jpn
-
Tsutsumi Akito
Department Of Medicine Ii Hokkaido University Graduate School Of Medicine
-
Koike Takao
Institute Of Molecular Cell Biology Okayama University School Of Medicine
-
YASUDA Shinsuke
Department of Medicine II, Hokkaido University Graduate School of Medicine
-
Atsumi Toru
Laboratory Of Developmental Immunology And The Core Research For Evolutional Science And Technology
-
Yasuda Shinsuke
Department Of Medicine Ii Hokkaido University Graduate School Of Medicine
-
Koike Takao
Department of Medicine II, Hokkaido University Graduate School of Medicine
関連論文
- Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation
- IFN-γ expression in CD8^+ T cells regulated by IL-6 signal is involved in superantigen-mediated CD4^+ T Cell death
- Perilipin Overexpression in White Adipose Tissue Induces a Brown Fat-Like Phenotype
- Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation
- A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)
- Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
- Polymyalgia rheumatica as the manifestation of unclassified aortitis
- Pathogenesis of antiphospholipid antibodies : Impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway
- The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β_2Glycoprotein I antibodies
- A Woman with Infectious Endocarditis Caused by Abiotrophia defectiva
- Two Cases of Systemic Lupus Erythematosus Complicated with Colonic Ulcers
- Identification of three novel peptides that inhibit CD40-CD154 interaction
- The Potential Role of Macrophage Migration Inhibitory Factor on the Migration of Vascular Smooth Muscle Cells
- A novel mutation of WFS1 gene in a Japanese man of Wolfram syndrome with positive diabetes-related antibodies
- Adult-onset Idiopathic Hypogonadotropic Hypogonadism due to Isolated Pituitary Gonadotropin Deficiency
- Involvement of the Cholinergic Pathway in the Pathogenesis of Pituitary Cushing's Syndrome
- Alternate Exon in the 5'-Untranslated Region of the Human ACTH Receptor Gene
- The inhibition of protein C anticoagulant activity by anti-β_2-glycoprotein I (β_2GPI) antibodies isolated from patients with antiphospholipid syndrome by chromatography methods
- The point mutation of tyrosine 759 of the IL-6 family cytokine receptor gp130 synergizes with HTLV-1 pX in promoting rheumatoid arthritis-like arthritis
- Antigenic structures recognized by anti-β2-glycoprotein I auto-antibodies
- Anti-β_2-glycoprotein I antibodies in children with atopic dermatitis
- 1-3). Antiphospholipid Syndrome
- A case of melorheostosis with linear sclerodermatous skin changes
- A novel missense mutation in the thyroid hormone receptor β gene in a kindred with resistance to thyroid hormone
- A Case of Deoxycorticosterone-Producing Adrenal Adenoma
- Cloning of a mouse adrenocorticotropin receptor-encoding gene
- Hepatic Manifestations of the Antiphospholipid Syndrome
- Abacterial prostatitis and primary biliary cirrhosis with Sjogren's syndrome
- Increased Fructose 2,6-bisphosphate in Peripheral Blood Mononuclear Cells of Patients with Diabetes
- Hemophagocytic Syndrome in Autoimmune Diseases
- Pulmonary Hypertension and the Antiphospholipid Syndrome
- Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome
- Zinc suppresses T_h17 development via inhibition of STAT3 activation
- Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy : a randomized trial
- Plasma gelsolin facilitates interaction between β2 glycoprotein I and α5β1 integrin
- The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8mg/week in patients with rheumatoid arthritis
- A comparison of pregnancy outcomes in Japanese women with type 2 and type 1 diabetes mellitus at tertiary centers
- Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematousus
- Aberrant splicing of the hRasGRP4 transcript and decreased levels of this signaling protein in the peripheral blood mononuclear cells in a subset of patients with rheumatoid arthritis
- Identification and functional analysis of novel calcium-sensing receptor gene mutation in familial hypocalciuric hypercalcemia